Sure. I'd be happy to. Thanks.
We took a number of steps. We contacted the people in charge of all the projects and asked for information on all their procurement protocols and risk reduction measures. We then created a list of all the measures that should be taken.
That includes patient screening; efforts to better match drugs to the patient's tolerance—as we've heard, to make sure they meet their needs—in the increasing toxic drug supply; risk-based protocols for assessing patient eligibility for take-home dosing; patient monitoring; and actions to address instances of diversion, which can include switching to observed dosing, transferring to different support services and removal from the program. There are more details behind each of those, but we pulled together all of those lists.
We are working with them to ensure they have the capacity to address those. They need to be able to put those measures in place so that we can absolutely reduce those risks.